Category: Latest News
-
U.S. Stocks Extend Yesterday’s Pullback As Nvidia, Oracle Slump
After coming under pressure over the course of the previous session, stocks saw further downside during trading on Wednesday. The major averages showed a lack of direction early in the session but slid more firmly into negative territory as the day progressed. The major averages finished the day off their worst levels but still moderately…
-
U.S. New Home Sales Jump, Surpassing Forecasts and Previous Month’s Figures
Recent data on U.S. New Home Sales shows a sharp rise in the annualized number of new single-family homes sold last month, reaching 800,000 units. This figure significantly exceeded analysts’ expectations of 650,000, beating forecasts by 150,000 units and highlighting strong demand in the housing market. Compared to the previous month’s 664,000 homes sold, this…
-
Oracle Shares Slip on Speculation of $15 Billion Bond Sale
Oracle (NYSE:ORCL) saw its stock drop more than 2% shortly after Wednesday’s market open amid reports that the software company is considering a $15 billion U.S. investment-grade bond offering. Bloomberg News, citing sources familiar with the matter, reported that Oracle may structure the debt sale in up to seven tranches, including a rare 40-year bond.…
-
Marvell Shares Climb Following $5 Billion Buyback Announcement
Marvell Technology, Inc. (NASDAQ:MRVL) shares rose 4.2% Wednesday morning after the semiconductor firm unveiled a new $5 billion stock repurchase authorization alongside a $1 billion accelerated share repurchase (ASR) program. The move builds on Marvell’s ongoing efforts to return capital to shareholders. As of August 2, 2025, the company had roughly $2 billion remaining under…
-
Alibaba Shares Surge on AI Expansion and Data Center Plans
Alibaba Group (NYSE:BABA) shares jumped Wednesday after the Chinese e-commerce titan unveiled plans to significantly boost spending on artificial intelligence infrastructure and revealed a new collaboration with AI powerhouse Nvidia (NASDAQ:NVDA). As of 8:44 AM ET, Alibaba ADRs traded in the U.S. were up 8.9% at $177.70, while shares listed in Hong Kong climbed 9.2%…
-
U.S. Crude Oil Stocks Dip Less Than Expected, Hinting at Slower Demand
U.S. crude oil inventories fell last week, according to the Energy Information Administration (EIA), but the decline was smaller than analysts had forecasted. The EIA reported that commercial crude oil stocks decreased by 607,000 barrels, below the expected drop of 800,000 barrels. Compared to the steep 9.285 million-barrel decline recorded the prior week, this week’s…
-
Levi Strauss Shares Reach 52-Week Peak at $23.41
Levi Strauss & Co. (NYSE:LEVI) Class A shares climbed to a 52-week high of $23.41, highlighting a strong upward trend over the past year. Over the last 12 months, the stock has gained 11.35%, signaling steady growth and growing investor confidence. The company’s market strength and strategic initiatives have contributed to this positive momentum, underscoring…
-
Copper Prices Jump as Freeport Details Production Hit from Grasberg Mine Suspension
Copper prices surged roughly 2% in intraday trading Wednesday after Freeport-McMoRan (NYSE:FCX) outlined the significant production shortfall caused by the suspension of its Grasberg Block Cave mine in Indonesia following a fatal mud rush. The mining giant confirmed that operations remain halted after two workers were killed, while search efforts continue for five missing employees.…
-
U.S. Building Permits Dip Slightly, Outperforming Weak Forecasts
U.S. building permits fell modestly in the latest report, registering a -2.3% change, slightly improving on economists’ dismal forecast of -3.7%. While the decline indicates some cooling in the construction sector, the numbers suggest the contraction is less severe than anticipated. Building permits, which reflect upcoming construction activity including financing, employment, and regulatory approvals, are…
-
uniQure Shares Skyrocket After Positive Huntington’s Disease Gene Therapy Data
uniQure N.V. (NASDAQ:QURE) stock surged 150% Wednesday following the announcement of encouraging topline results from its pivotal Phase I/II study of AMT-130 in patients with Huntington’s disease, showing substantial slowing of disease progression compared to controls. The trial successfully hit its primary endpoint, with high-dose AMT-130 demonstrating a 75% reduction in disease progression at 36…